BP’s PhenomeX Inc. Common Stock CELL Stock Holding History

BP’s Portfolio CELL Stock Details CELL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,773	Closed	-$340K	–	592
2021 Q1	$340K	Buy	+6,773	New	+$462K	0.01%	546

Other funds holding CELL

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BP's CELL Position: Q2 2021 in Review

BP sold out of PhenomeX Inc. Common Stock (CELL) in Q2 2021, closing a stake of 6,773 shares — an estimated $340K sold.

BP first reported a position in CELL in Q1 2021 and held it in 1 quarter. The position peaked at $340K in Q1 2021. 156 funds tracked by Wall St. Rank hold CELL as of Q2 2021.

BP reported no remaining PhenomeX Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
BP sold 6,773 PhenomeX Inc. Common Stock shares in Q2 2021, an estimated $340K.
BP first reported a position in PhenomeX Inc. Common Stock in Q1 2021 and held it in 1 quarter.
BP's PhenomeX Inc. Common Stock position peaked at $340K in Q1 2021.
156 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q2 2021.

Based on BP's 13F filing for Q2 2021, filed 9 Aug 2021.